Panobinostat in treatment of multiple myeloma

Most patients with multiple myeloma (MM) have even in the era new drugs an incurable disease. Deacetylase inhibitors (DACi) extend the possibilities in MM treatment. Effects in MM is through targeting of epigenetic and protein metabolism pathways. Panobinostat, pan DCAi, in combination with bortezomib and dexamethasone was approved for treatment in patients with relapsed or refractory MM. Results of clinical study a phase 3 showed improved progression free survival and overall response rate. Adverse events this combination included thrombocytopenia, diarrhoea, fatigue and peripheral neuropathy. Research how to maintain effect while improving tolerability is ongoing. (author)